Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases.

Key market opportunities in cell and gene therapy include tracking investment trends, analyzing key deals, and staying updated with scientific developments and market forecasts. The publication is ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on ...

Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in 2026. When you purchase through links on our site, we may earn an affiliate ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Operational real-world data analyzed from patients prescribed ZYNTEGLO™ and LYFGENIA™ Oral presentation of recent patient experience data demonstrating the value proposition of gene therapy More than ...

Qure (QURE) is back on traders’ radar after a sharp 9% one day decline, prompting fresh attention on how its gene therapy ...

WASHINGTON (AP) — Shares of beleaguered drugmaker Sarepta Therapeutics (SRPT) jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, ...